quote from Pharmaceutical Business from 13 March 2008.NB the...

quote from Pharmaceutical Business from 13 March 2008.
NB the last paragraph. Buying under 40 cents is a steal...
Quote
"Avexa's apricitabine found effective in Phase II HIV trial
13th March 2008
By Staff Writer
Biotech firm Avexa has announced encouraging 48 week data from the apricitabine's Phase IIb clinical trial.








RELATED ARTICLESAvexa: trial success creates takeover speculation
21 Mar 2007
Monogram and Avexa sign HIV drug research agreement
11 Mar 2008
Avexa HIV drug meets trial goal
22 Mar 2007
Avexa's apricitabine found effective in Phase II HIV trial
13 Mar 2008
Avexa initiates Phase III trial of HIV drug
4 Jan 2008
COMPANIES MENTIONEDAftermarket Technology Corp.
WHITE PAPERS
No White Papers Available

At week 48 the proportion of patients with HIV levels below detectable was over 90%. Patients who were initially treated with 3TC but who changed to apricitabine (ATC) at week 24 also improved their response after their switch to ATC.

Avexa also reported that the CD4 cell count of ATC treated patients continued to increase out to 48 weeks. Patients initially treated with 3TC and then switched to ATC doubled their levels of CD4 cell count at week 48 (after 24 weeks of ATC) compared to their CD4 cell count after 24 weeks of 3TC.

No ATC resistance has been identified after 48 weeks of therapy. This demonstrated ability of ATC to withstand selection of HIV resistance, even in patients who have already failed other drugs, and differentiates it from some of the other HIV drugs in clinical use.

Julian Chick, CEO of Avexa, said: "These 48 week results clearly define ATC as a drug with huge potential both for drug-resistant patients in need of potent and safe new HIV therapies and for patients whose regimen currently contains 3TC."
End Quote.
Glaxo Smith Kline will obviously be courting Avexa.